Item 7.01 Regulation FD Disclosure.
On January 10, 2022, CytomX Therapeutics, Inc. (the "Company") posted its
corporate presentation relating to its research and development programs to be
presented at the 40th Annual J.P. Morgan Healthcare Conference to the investor
section of the Company's website
at: https://ir.cytomx.com/events-and-presentations. The Company's corporate
presentation is attached hereto as Exhibit 99.1.
The furnishing of the attached presentation is not an admission as to the
materiality of any information therein. The information contained in the slides
is summary information that is intended to be considered in the context of more
complete information included in the Company's filings with the U.S. Securities
and Exchange Commission (the "SEC") and other public announcements that the
Company has made and may make from time to time by press release or otherwise.
The Company undertakes no duty or obligation to update or revise the information
contained in this report, although it may do so from time to time as its
management believes is appropriate. Any such updating may be made through the
filing of other reports or documents with the SEC, through press releases or
through other public disclosures. For important information about forward
looking statements, see the slide titled "Forward-Looking Statements" in Exhibit
99.1 attached hereto.
The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit
99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of
the Exchange Act or otherwise subject to the liabilities of that section or
Sections 11 and 12(a)(2) of the Securities Act. The information contained in
this Item 7.01 and in the presentation attached as Exhibit 99.1 to this Current
Report shall not be incorporated by reference into any filing with the SEC made
by the Company, whether made before or after the date hereof, regardless of any
general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Corporate Presentation of CytomX Therapeutics, Inc. dated January
10, 2022.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
© Edgar Online, source Glimpses